KRAS mRNA vaccine for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This early-phase trial is testing a new mRNA vaccine (ABO2102) designed to target KRAS mutations in advanced solid tumors. It may be an option if your cancer has a KRAS mutation and standard treatments are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced solid tumors (like pancreatic or lung cancer) that have worsened after at least one treatment, or if you haven’t had treatment yet, your doctor believes this trial may still benefit you.
- Your tumor has a specific change in the KRAS gene.
- You are generally able to do daily activities (ECOG score 0-2).
- You have not had a KRAS cancer vaccine before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a lab-made immune cell (T-cell) treatment that targets a specific KRAS mutation (G12V) found in some pancreatic cancers. It may help shrink tumors or control cancer growth after standard treatment, and it mainly focuses on safety and early effectiveness.
This trial tests a new vaccine, ABO2102, for people with advanced solid tumors that have a specific change in the KRAS gene. The vaccine aims to help your immune system fight the cancer.
This trial tests a new drug called ABSK211 in people with advanced solid tumors that have a change in the KRAS gene. The goal is to see if the drug is safe and works against the cancer.
This trial tests a vaccine designed to target cancers with KRAS mutations. It may be an option if your cancer has a KRAS mutation and you have either tried other treatments without success or have a newly diagnosed, early-stage lung adenocarcinoma.
This trial tests a personalized vaccine designed to target cancers with specific KRAS gene mutations. It may be an option for adults whose advanced solid tumor (like pancreatic or lung cancer) has not responded to standard treatments.
This trial tests a new vaccine that targets KRAS mutations in patients with colorectal or pancreatic cancer after surgery and chemotherapy. The goal is to see if the vaccine can help prevent the cancer from coming back.
Hear when a new Pancreatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.